HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

European Chemicals Agency's list of "substances of very high concern" (SVHCs) is likely to have profound effect on chemical production and use in the U.S., according to Sept. 30 report issued by Environmental Defense Fund. Chemicals deemed SVHCs are those identified by REACH as carcinogenic, mutagenic, reproductive toxins, bioaccumulative or otherwise injurious to human health. Use of SVHCs will have to be authorized by ECHA; a first draft of the SVHC list is likely to be released in late October. While ECHA's proposed SVHC list currently has 16 chemicals, Environmental Defense Fund says pressure from advocacy organizations could balloon list to nearly 300 chemicals, many of which are in active commerce in the U.S. - a move that would have "a major impact on chemical production" in this country. Some of the 300 chemicals are used in personal care or in personal-care packaging, such as formaldehyde and bisphenol A. The Environmental Defense Fund report, plus a list of the chemicals, is available at 1www.edf.org

You may also be interested in...

Global AMR R&D Hub launches Dynamic Data Dashboard

The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.

AzarGen And iBio Push On With Plant-Based Rituximab

AzarGen and iBio have advanced their alliance, with the latter revealing it would now begin manufacturing and characterizing additional supplies of plant-based rituximab, to enable pre-clinical studies comparing it with Roche’s MabThera original.

EMA Panexcell Review Leads Tillomed To Pull Doxorubicin

Emcure’s Tillomed has been forced to withdraw its application for a version of doxorubicin, in light of the EMA taking a closer look at medicines for which study data prepared by Panexcell Clinical Laboratories was used to support marketing authorization applications.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts